Expression levels of resistant genes affect cervical cancer prognosis

Yang,Fengmei; Gao,Bo; Li,Rui; Li,Wencui; Chen,Wei; Yu,Zongtao; Zhang,Jicai

doi:10.3892/mmr.2017.6328

Expression levels of resistant genes affect cervical cancer prognosis

Authors:
- Fengmei Yang
- Bo Gao
- Rui Li
- Wencui Li
- Wei Chen
- Zongtao Yu
- Jicai Zhang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Department of Laboratory Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Department of Infection Control, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China
Published online on: March 15, 2017 https://doi.org/10.3892/mmr.2017.6328
Pages: 2802-2806

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor cells may develop multidrug resistance (MDR) to various chemotherapy regimens. Such resistance reduces the sensitivity of cells to chemotherapy drugs, leading to the failure of cervical cancer (CC) treatment and disease progression. The present study aimed to investigate the role of MDR1, lung resistance protein (LRP) and placental glutathione S‑transferase π 1 (GSTP1) in CC and MDR, and the prognostic value of these genes. The mRNA expression levels of these resistance‑associated genes were determined in 47 CC and 20 healthy cervical tissue samples. Subsequently, the data was analyzed alongside clinicopathological parameters. The mRNA expression levels of MDR1, LRP and GSTP1 in CC were 0.57±0.32, 0.58±0.29 and 0.44±0.24, respectively, whereas those in healthy cervical tissues were 0.19±0.10, 0.17±0.14 and 0.18±0.10, respectively. Therefore, the expression levels of these genes were significantly greater in CC compared with healthy cervical tissue (P<0.05). mRNA expression levels of MRD1 were increased in the well differentiated group (0.68±0.27) compared with the poorly differentiated group (0.38±0.33; P<0.05). No significant differences were observed between LRP and GSTP1 mRNA expression levels and tumor differentiation or clinical stage of the patients (P>0.05). Multivariate logistic regression indicated that the degree of differentiation and the MDR1 gene expression levels were predictors of CC prognosis (P<0.05). The survival rate of patients in the MDR1‑negative group was significantly greater compared with the MDR1‑positive group (P<0.05). The results of the present study therefore suggested that MDR1 gene expression is a predictor of poor survival in CC.

View Figures

View References

1	Aggarwal P: Cervical cancer: Can it be prevented? World J Clin Oncol. 5:775–780. 2014. View Article : Google Scholar : PubMed/NCBI
2	Fojo A, Hamilton TC, Young RC and Ozols RF: Multidrug resistance in ovarian cancer. Cancer. 60:(8 Suppl). S2075–S2080. 1987. View Article : Google Scholar
3	Gong J, Jaiswal R, Mathys JM, Combes V, Grau GE and Bebawy M: Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev. 38:226–234. 2012. View Article : Google Scholar : PubMed/NCBI
4	Lage H: Gene therapeutic approaches to overcome ABCB1-Mediated drug resistance. Recent Results Cancer Res. 209:87–94. 2016. View Article : Google Scholar : PubMed/NCBI
5	Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR and Scheper RJ: Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer. 65:230–237. 1996. View Article : Google Scholar : PubMed/NCBI
6	Wu L, Shen Y, Peng X, Zhang S, Wang M, Xu G, Zheng X, Wang J and Lu C: Aberrant promoter methylation of cancer-related genes in human breast cancer. Oncol Lett. 12:5145–5155. 2016.PubMed/NCBI
7	Karabulut S, Kaya Z, Amuran GG, Peker I, Özmen T, Gūllūoḡlu BM, Kaya H, Erzik C, Ōzer A and Akkiprik M: Correlation between the DNA methylation and gene expression of IGFBP5 in breast cancer. Breast Dis. 36:123–131. 2016. View Article : Google Scholar : PubMed/NCBI
8	Dong X and Mumper RJ: Nanomedicinal strategies to treat multidrug-resistant tumors: Current progress. Nanomedicine (Lond). 5:597–615. 2010. View Article : Google Scholar : PubMed/NCBI
9	Li WT, Aizimu A and Wang YH: Relationship between the expression of P-glycoprotein and the therapeutic effect of neoadjuvant chemotherapy on Uygur and Han patients with cervical cancer. J Chin Pract Diagn Ther. 25:225–227. 2011.
10	Tydén E, Skarin M and Höglund J: Gene expression of ABC transporters in Cooperia oncophora after field and laboratory selection with macrocyclic lactones. Mol Biochem Parasitol. 198:66–70. 2014. View Article : Google Scholar : PubMed/NCBI
11	Zhang Q, Wang J, He H, Liu H, Yan X and Zou K: Trametenolic acid B reverses multidrug resistance in breast cancer cells through regulating the expression level of P-glycoprotein. Phytother Res. 28:1037–1044. 2014. View Article : Google Scholar : PubMed/NCBI
12	Stewart DJ: Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol. 75:173–234. 2010. View Article : Google Scholar : PubMed/NCBI
13	Wood N and Streckfus CF: The expression of lung resistance protein in saliva: A novel prognostic indicator protein for carcinoma of the breast. Cancer Invest. 33:510–515. 2015. View Article : Google Scholar : PubMed/NCBI
14	Lu D, Shi HC, Wang ZX, Gu XW and Zeng YJ: Multidrug resistance-associated biomarkers PGP, GST-π, Topo-II and LRP as prognostic factors in primary ovarian carcinoma. Br J Biomed Sci. 68:69–74. 2011. View Article : Google Scholar : PubMed/NCBI
15	Li YJ, Yu CH, Zhang W and Liu Y and Liu Y: The relationship between expression of COX-2′LRP and metastasis and prognosis in patients with non-small cell lung carcinoma. J Clin Pulm Med. 15:1707–1709. 2010.
16	Jiao JW and Wen F: Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. Oncol Rep. 25:781–788. 2011.PubMed/NCBI
17	Zhong H, Zuo Y, Wu X, Peng Y, He H, Yang J, Guan C and Xu Z: Synergistic antitumor effect of amorphigenin combined with cisplatin in human lung adenocarcinoma A549/DDP cells. Zhongguo Fei Ai Za Zhi. 19:805–812. 2016.(In Chinese). PubMed/NCBI
18	Daukantienė L, Kazbarienė B, Valuckas KP, Didžiapetrienė J, Krikštaponienė A and Aleknavičius E: The significance of reduced glutathione and glutathione S-transferase during chemoradiotherapy of locally advanced cervical cancer. Medicina (Kaunas). 50:222–229. 2014. View Article : Google Scholar : PubMed/NCBI
19	Sato A, Shimada K, Nakamachi M, Ushio J, Yamamoto W, Kurihara M and Matsukawa M: Effectiveness of doxifluridine (5′-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens. Gastric Cancer. 5:233–236. 2002. View Article : Google Scholar : PubMed/NCBI
20	Nagai N1, Shiroyama Y, Oshita T, Mukai K, Shigemasa K, Fujii T, Katsube Y, Matsubayashi S, Murakami T and Ohama K: Tumor dihydropyrimidine dehydrogenase activity in advanced cervical carcinoma. Oncol Rep. 9:1033–1040. 2002.PubMed/NCBI
21	Lou JY, Peng ZL, Zheng Y, Wang H, He B and Wang HJ: Reversal of multi-drug resistance in ovarian cancer cell by RNA interference. Zhonghua Fu Chan Ke Za Zhi. 41:413–416. 2006.PubMed/NCBI
22	Gao GL, Tu KJ and Liu FJ: Expression and reversal of multi-drug resistance gene in ovarian cancer. Chin Clin Oncol. 15:870–873. 2010.